Published in AIDS on November 28, 2012
Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes. J Virol (2014) 0.77
Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants. EBioMedicine (2016) 0.76
Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response. Retrovirology (2013) 0.76
A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support. Retrovirology (2016) 0.75
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Subgenotype analysis of Cryptosporidium isolates from humans, cattle, and zoo ruminants in Portugal. J Clin Microbiol (2003) 3.03
Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLoS Comput Biol (2007) 2.25
Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS (2014) 2.02
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis (2013) 1.90
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther (2011) 1.90
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir Ther (2012) 1.56
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer (2010) 1.53
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS (2006) 1.52
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS (2007) 1.51
Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting. Eur J Epidemiol (2004) 1.50
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer (2004) 1.39
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis (2007) 1.39
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine (2011) 1.37
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35
Distribution of Cryptosporidium subtypes in humans and domestic and wild ruminants in Portugal. Parasitol Res (2006) 1.34
Acute kidney injury in patients with sepsis: a contemporary analysis. Int J Infect Dis (2008) 1.31
Long-term risk of mortality after acute kidney injury in patients with sepsis: a contemporary analysis. BMC Nephrol (2010) 1.17
Identification of potentially human-pathogenic Enterocytozoon bieneusi genotypes in various birds. Appl Environ Microbiol (2006) 1.13
Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic. Infect Genet Evol (2008) 1.10
Cryptosporidium felis and C. meleagridis in persons with HIV, Portugal. Emerg Infect Dis (2004) 1.09
Acute renal failure in patients with sepsis. Crit Care (2007) 1.09
Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis. Nephrol Dial Transplant (2011) 1.05
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine (2009) 1.05
Genotypes of Enterocytozoon bieneusi in mammals in Portugal. J Eukaryot Microbiol (2006) 1.04
20 years of HIV-2 infection in Portugal: trends and changes in epidemiology. Clin Infect Dis (2009) 1.04
Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. J Gen Virol (2011) 1.03
Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci (2012) 1.01
High genetic diversity of human immunodeficiency virus type 1 in Angola. AIDS Res Hum Retroviruses (2005) 0.99
Prognostic utility of RIFLE for acute renal failure in patients with sepsis. Crit Care (2007) 0.99
Hepatitis delta in HIV-infected individuals in Europe. AIDS (2011) 0.99
Acute renal failure in critically ill HIV-infected patients. Crit Care (2007) 0.97
Microsporidia as emerging pathogens and the implication for public health: a 10-year study on HIV-positive and -negative patients. Int J Parasitol (2012) 0.97
Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance. Antimicrob Agents Chemother (2009) 0.95
Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms. J Clin Microbiol (2003) 0.95
Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes. Clin Vaccine Immunol (2010) 0.94
Population structure of Pneumocystis jirovecii isolated from immunodeficiency virus-positive patients. Infect Genet Evol (2010) 0.94
The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients. Retrovirology (2008) 0.93
Dopamine-induced conformational changes in alpha-synuclein. PLoS One (2009) 0.93
HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. J Virol (2010) 0.93
Outbreak of acute respiratory infection among infants in Lisbon, Portugal, caused by human adenovirus serotype 3 and a new 7/3 recombinant strain. J Clin Microbiol (2010) 0.91
Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal. J Antimicrob Chemother (2006) 0.91
Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy. Biochem J (2005) 0.91
The case of the disappearing mycobacteria in Ziehl-Neelsen-stained smears. Int J Infect Dis (2011) 0.90
Recent advances in antiretroviral treatment and prevention in HIV-infected patients. Curr Opin HIV AIDS (2011) 0.90
Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology (2003) 0.90
Occurrence and molecular characterization of Cryptosporidium spp. in mammals and reptiles at the Lisbon Zoo. Parasitol Res (2005) 0.88
An assessment of the RIFLE criteria for acute renal failure in critically ill HIV-infected patients. Crit Care (2007) 0.88
Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Antivir Ther (2014) 0.88
Unraveling Mycobacterium tuberculosis genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting. BMC Genomics (2014) 0.88
Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother (2010) 0.88
Tuberculosis, a re-emergent disease. Eur J Radiol (2005) 0.87
Origin and epidemiological history of HIV-1 CRF14_BG. PLoS One (2011) 0.87
Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals. J Virol (2004) 0.87
Distribution of Cryptosporidium species and subtypes in water samples in Portugal: a preliminary study. J Eukaryot Microbiol (2006) 0.87
Microsporidia detection in stools from pets and animals from the zoo in Portugal: a preliminary study. J Eukaryot Microbiol (2003) 0.87
Diagnostic use of 3 techniques for identification of microsporidian spores among AIDS patients in Portugal. Scand J Infect Dis (2002) 0.87
Hansen's disease in an HIV patient complicated by deep vein thrombosis: a rare complication of thalidomide therapy. Eur J Dermatol (2009) 0.86
Energy-independent translocation of cell-penetrating peptides occurs without formation of pores. A biophysical study with pep-1. Mol Membr Biol (2007) 0.86
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS (2013) 0.86
HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique. J Acquir Immune Defic Syndr (2009) 0.86
Insulin glycation by methylglyoxal results in native-like aggregation and inhibition of fibril formation. BMC Biochem (2011) 0.86
Phylogenetic demonstration of two cases of perinatal human immunodeficiency virus type 2 infection diagnosed in adulthood. AIDS Res Hum Retroviruses (2004) 0.85
Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients. J Virol (2010) 0.84
Seronegative infection and AIDS caused by an A2 subsubtype HIV-1. AIDS (2004) 0.84
Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection. PLoS One (2011) 0.83
Pneumocystis jiroveci in Portuguese immunocompromised patients: association of specific ITS genotypes with treatment failure, bad clinical outcome and childhood. Infect Genet Evol (2003) 0.83
Pneumocystis jirovecii carriage in Portuguese immunocompetent patients: preliminary results. J Eukaryot Microbiol (2003) 0.83
Fold-unfold transitions in the selectivity and mechanism of action of the N-terminal fragment of the bactericidal/permeability-increasing protein (rBPI(21)). Biophys J (2009) 0.83
Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins. J Clin Microbiol (2006) 0.83
Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. J Virol (2010) 0.83
Direct treatment costs of HIV/AIDS in Portugal. Rev Saude Publica (2013) 0.82